Search results for " Respiratory System"

showing 10 items of 851 documents

Relaxin in Obstructive Sleep Apnea: Relationship with Blood Pressure and Inflammatory Mediators

2015

<b><i>Background:</i></b> Obstructive sleep apnea (OSA) is associated with nocturnal intermittent hypoxia, which may be responsible for increased circulating levels of vascular endothelial growth factor (VEGF) and inflammatory mediators, such as metalloproteinases (MMPs), and which contributes to the pathogenesis of systemic hypertension. Why some OSA patients remain normotensive is poorly understood. Relaxin-2, a pregnancy hormone, may sometimes circulate in men and could increase in hypoxic conditions. It exerts a vasodilatory activity and can modulate the release of molecules, such as MMPs and VEGF. <b><i>Objectives:</i></b> The objective o…

AdultMaleVascular Endothelial Growth Factor APulmonary and Respiratory Medicinemedicine.medical_specialtyAmbulatory blood pressurePolysomnographyBlood PressurePolysomnographySettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRelaxin · Obstructive sleep apnea · Metalloproteinase · Vascular endothelial growth factorInterquartile rangeInternal medicineRespiratory disturbance indexmedicineHumansHypoxiaInflammationSleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-1medicine.diagnostic_testbusiness.industryRelaxinSleep apneaTissue Inhibitor of MetalloproteinasesIntermittent hypoxiaMiddle Agedmedicine.diseaseMatrix MetalloproteinasesObstructive sleep apneaEndocrinologyBlood pressureMatrix Metalloproteinase 9030228 respiratory systemHypertensionMatrix Metalloproteinase 2Inflammation MediatorsbusinessRespiration
researchProduct

Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data

2018

Background The X-ACT study aims to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1-antihistamines. Methods In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18–75 years) with ≥4 angioedema episodes during the 6 months before inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks. Angioedema-related QoL, skin-related QoL impairment, and psychological well-being were assessed. Results Ninety-one patients were randomized and 68 (omalizumab, n=35; placebo, n=33) completed the 28-week treatment period. At baselin…

AdultMalechronic spontaneous urticariamedicine.medical_specialtyAdolescentUrticariaImmunologyOmalizumab600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::616 KrankheitenPlaceboYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDouble-Blind MethodRefractoryQuality of lifeInternal medicine616Anti-Allergic AgentsmedicineHumansH1-antihistamine-refractoryImmunology and AllergyDepression (differential diagnoses)AgedAngioedemaAdult patientsbusiness.industryangioedemaDermatology Life Quality IndexMiddle AgedSurgeryquality of life030228 respiratory systemExperimental Allergy and ImmunologyomalizumabOriginal ArticleFemaleORIGINAL ARTICLESH1‐antihistamine‐refractorymedicine.symptombusinessmedicine.drugAllergy
researchProduct

Unfractionated Heparin Versus Subcutaneous Nadroparin in Adults Supported With Venovenous Extracorporeal Membrane Oxygenation: a Retrospective, Multi…

2021

Extracorporeal membrane oxygenation (ECMO) requires constant management of coagulation. Whereas unfractionated heparin remains the anticoagulant of choice, experienced centers report high bleeding rates. Biocompatibility of the extracorporeal circuit enables management of anticoagulation with subcutaneous low-molecular-weight heparins only. The aim of this study was to evaluate the safety and feasibility of anticoagulation with subcutaneous nadroparin compared with unfractionated heparin during respiratory ECMO in patients. We assessed for thrombotic complications and number of bleeding and life-threatening bleeding events. Additionally, we evaluated the change in resistance to flow in the …

AdultMalemedicine.drug_classmedicine.medical_treatmentBiomedical EngineeringBiophysicsBioengineering030204 cardiovascular system & hematologyExtracorporealBiomaterials03 medical and health sciencesExtracorporeal Membrane Oxygenation0302 clinical medicineExtracorporeal membrane oxygenationmedicineHumansanticoagulationOxygenatorRetrospective Studiesextracorporeal oxygenationHeparinbusiness.industryAnticoagulantAnticoagulantsThrombosisRetrospective cohort studyGeneral MedicineHeparinMiddle Agedunfractionated heparin030228 respiratory systemCoagulationAnesthesiaNadroparinnadroparinFemalebusinessmedicine.drugASAIO Journal
researchProduct

Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.

2019

Background An estimated 7% of patients with asthma have chronic rhinosinusitis with nasal polyps (CRSwNP), and more than 80% have at least some radiographic evidence of sinonasal inflammation. Aspirin sensitivity is strongly associated with elevated blood eosinophil levels and increased asthma severity. Intravenous (IV) reslizumab has been shown to improve asthma control in patients with nasal polyps. Objective These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity. Methods Patients aged 12-75 years with e…

AdultMalemedicine.medical_specialtyAdolescentComorbidityPlaceboAntibodies Monoclonal Humanized03 medical and health sciencesYoung Adult0302 clinical medicineNasal PolypsReslizumabMaintenance therapyInternal medicinemedicineImmunology and AllergyHumansNasal polyps030212 general & internal medicineAnti-Asthmatic AgentsPulmonary EosinophiliaSinusitisChildAsthmaAgedRhinitisAspirinbusiness.industryMinimal clinically important differenceAnti-Inflammatory Agents Non-SteroidalEosinophilMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsmedicine.anatomical_structureTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireChronic DiseaseFemaleSelf Reportbusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Psychiatric symptoms in patients with post-H1N1 narcolepsy type 1 in Norway.

2019

Study objectives Several studies have reported psychiatric comorbidity in patients with narcolepsy type 1 (NC1). The primary aim of this study was to explore the extent of psychiatric symptoms in a cohort of Norwegian NC1 patients, most of whom were H1N1-vaccinated. We also wanted to explore possible causes of the psychiatric symptoms seen in NC1. Methods Cross-sectional study. Psychiatric symptoms were assessed by the Achenbach System of Empirically Based Assessment (ASEBA) Child Behavior Check List (CBCL) in children and by Adult Self Report (ASR) in adults. Results The mean (SD) total T-scores were 58.6 (9.2) for children and 57.0 (9.8) for adults, these being mainly driven by internaliz…

AdultMalemedicine.medical_specialtyAdolescentExcessive daytime sleepinessCBCLNorwegianCohort Studies03 medical and health sciences0302 clinical medicineInfluenza A Virus H1N1 SubtypePhysiology (medical)Surveys and QuestionnairesInfluenza HumanmedicinePandemrixHumansIn patientPsychiatryChildNarcolepsyOrexinsbusiness.industryNorwayMental Disordersmedicine.diseaselanguage.human_languageCross-Sectional Studies030228 respiratory systemInfluenza VaccinesCohortlanguageSleep DeprivationFemaleNeurology (clinical)medicine.symptombusinessCheck List030217 neurology & neurosurgeryNarcolepsySleep
researchProduct

Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled …

2016

Background Chronic spontaneous urticaria (CSU) severely impacts quality of life (QoL), especially in patients with wheals and angioedema. Omalizumab is approved as add-on therapy for CSU patients; however, its effect on patients who are double-positive for wheals and angioedema has not been systematically studied. Objective The primary objective was to evaluate the efficacy of omalizumab vs placebo at week 28 using the Chronic Urticaria Quality of Life (CU-Q2oL) questionnaire. Number of angioedema-burdened days, time interval between successive angioedema episodes, disease activity, angioedema-specific and overall QoL impairment were secondary objectives. Methods X-ACT was a phase III, rand…

AdultMalemedicine.medical_specialtyAdolescentUrticariamedicine.medical_treatmentImmunologyDrug ResistanceOmalizumabOmalizumabPlacebolaw.inventionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifeimmune system diseaseslawInternal medicineAnti-Allergic AgentsmedicineHumansImmunology and AllergyAngioedemaYoung adultskin and connective tissue diseasesAdverse effectAgedAngioedemabusiness.industryMiddle AgedTreatment Outcome030228 respiratory systemAnesthesiaChronic DiseaseRetreatmentHistamine H1 AntagonistsQuality of LifeFemaleAntihistaminemedicine.symptombusinessmedicine.drugAllergy
researchProduct

Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.

2019

Background Hypersensitivity reactions to platinum salts (PS) (cisplatin [CI], carboplatin [CA], and oxaliplatin [OX]) can be severe and their incidence is increasing due to their widespread use in cancer treatment. Objective To determine the rate of cross-reactivity between PS and whether CI can be administered without prior allergy testing in patients with a history of CA or OX hypersensitivity. Methods From September 2002 to April 2016, patients with suspected immediate PS hypersensitivity were tested and cross-reactivity between the 3 PS was evaluated. We then studied patients who were given CI without desensitization after immediate hypersensitivity to other PS. Results A total of 155 p…

AdultMalemedicine.medical_specialtyAllergymedicine.medical_treatment[SDV]Life Sciences [q-bio]Antineoplastic AgentsPlatinum CompoundsCross ReactionsGastroenterologyCarboplatinDrug Hypersensitivity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineNeoplasmsImmunology and AllergyMedicineHumans030212 general & internal medicineDesensitization (medicine)AgedSkin TestsCisplatinAged 80 and overChemotherapybusiness.industryMiddle Agedmedicine.diseaseConfidence intervalCarboplatin3. Good healthOxaliplatinOxaliplatin030228 respiratory systemchemistryFemaleSaltsbusinessAnaphylaxismedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis

2017

Background Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc), representing the main cause of death in these patients. The identification of parameters that can predict the early onset and progression of ILD in SSc represents an unmet need in clinical practice. The study was designed to explore whether the surfactant proteins (SP) A and D may be used as noninvasive tools for the early identification of ILD in SSc. Alveolar exhaled nitric oxide (NO) was investigated as a surrogate marker of distal inflammation. Methods Unselected consecutive subjects newly diagnosed with scleroderma and subjects free of respiratory and systemic diseases were recruited. All pat…

AdultMalemedicine.medical_specialtyBreath TestSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySclerodermaScleroderma03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineDLCOInternal medicineMedicineHumansRespiratory systemLungScleroderma Systemicbusiness.industryPulmonary surfactant-associated proteinMedicine (all)SystemicInterstitial lung diseaseSurfactant protein DNitric oxideGeneral MedicineBiomarkerrespiratory systemmedicine.diseasePulmonary Surfactant-Associated Protein Dmedicine.anatomical_structure030228 respiratory systemBreath Tests030220 oncology & carcinogenesisLung diseaseExhaled nitric oxideFemalebusinessInterstitialLung Diseases InterstitialBiomarkersHuman
researchProduct

Smoking in COPD Patients: A New Clinical Phenotype?

2017

AdultMalemedicine.medical_specialtyCopd patientsmedicine.medical_treatmentMEDLINEPulmonary diseaseSymptom assessmentPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineForced Expiratory VolumeInternal medicinePrevalencemedicineHumans030212 general & internal medicineClinical phenotypeAgedAged 80 and overbusiness.industrySmokingGeneral MedicineMiddle AgedPhenotypePhenotype030228 respiratory systemSpainSmoking cessationFemaleSmoking CessationSymptom AssessmentbusinessArchivos de Bronconeumología (English Edition)
researchProduct

Criteria deemed important by the relatives for designating a reference person for patients hospitalized in ICU

2020

Abstract Purpose We investigated the criteria that patients' relatives deem important for choosing, among themselves, the person best qualified to interact with the caregiving staff. Methods Exploratory, observational, prospective, multicentre study between 1st March and 31st October 2018 in 2 intensive care units (ICUs). A 12-item questionnaire was completed anonymously by family members of patients hospitalized in the ICU 3 and 5 days after the patient's admission. Relatives were eligible if they understood French and if no surrogate had been appointed by the patient prior to ICU admission. More than one relative per patient could participate. Results In total, 87 relatives of 73 patients…

AdultMalemedicine.medical_specialtyCritical Care[SDV]Life Sciences [q-bio]Decision MakingEmotionsCritical Care and Intensive Care MedicineProxy (climate)law.invention03 medical and health sciences0302 clinical medicineClinical historylawSurveys and QuestionnairesIntensive careHumansMedicineFamilyProspective StudiesAgedbusiness.industry030208 emergency & critical care medicineMiddle AgedIntensive care unitIcu admissionHospitalizationIntensive Care UnitsFamily memberCaregivers030228 respiratory systemSpouseFamily medicineFemaleObservational studyFamily RelationsbusinessJournal of Critical Care
researchProduct